A specific genetic variant of SCN1A may be associated with earlier-onset epilepsy. SCN1A variants are most commonly associated with Dravet syndrome, the most common genetic epilepsy, which is ...

Designation based on preliminary clinical evidence indicating the potential for ETX101 to address unmet medical needs associated with SCN1A+ Dravet syndrome Completion of enrollment in POLARIS ...

A scientific discovery may help children suffering from Dravet syndrome. Innovative gene therapy may help treat a severe and fatal developmental epilepsy syndrome that affects children. Researchers ...

This article originally appeared in Knowable Magazine. The seizures started when Samantha Gundel was just four months old. By her first birthday, she was taking a cocktail of three different ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics today announced the upcoming presentation of initial data from the ENVISION prospective natural history study of children with SCN1A+ ...

The seizures started when Samantha Gundel was just four months old. By her first birthday, she was taking a cocktail of three different anticonvulsant medicines. A vicious cycle of recurrent pneumonia ...

Scientists from the University of Virginia (UVA) School of Medicine describe in a study involving mouse models how a newly developed gene therapy can treat Dravet syndrome, a severe form of epilepsy, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gene expression, today announced the presentation of in vivo ...

Researchers have discovered a specific genetic variant in SCN1A, the most common genetic epilepsy, that leads to an earlier onset of epilepsy, with clinical features distinct from other epilepsies.